Publication | Closed Access

AD-O53.2—a novel recombinant fusion protein combining the activities of TRAIL/Apo2L and Smac/Diablo, overcomes resistance of human cancer cells to TRAIL/Apo2L

MedicineApoptosisMolecular BiologyCancer Cell BiologyCancer BiologyCell BiologyCancer ResearchHuman Cancer Cells